GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » PB Ratio

Samsung BioLogics Co (XKRX:207940) PB Ratio : 6.82 (As of Apr. 12, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-12), Samsung BioLogics Co's share price is ₩1045000.00. Samsung BioLogics Co's Book Value per Share for the quarter that ended in Dec. 2024 was ₩153,211.51. Hence, Samsung BioLogics Co's PB Ratio of today is 6.82.

The historical rank and industry rank for Samsung BioLogics Co's PB Ratio or its related term are showing as below:

XKRX:207940' s PB Ratio Range Over the Past 10 Years
Min: 2.48   Med: 6.63   Max: 13.65
Current: 6.82

During the past 11 years, Samsung BioLogics Co's highest PB Ratio was 13.65. The lowest was 2.48. And the median was 6.63.

XKRX:207940's PB Ratio is ranked worse than
85.2% of 1284 companies
in the Biotechnology industry
Industry Median: 2.02 vs XKRX:207940: 6.82

During the past 12 months, Samsung BioLogics Co's average Book Value Per Share Growth Rate was 10.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 27.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 21.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 13.40% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Samsung BioLogics Co was 27.10% per year. The lowest was 2.20% per year. And the median was 13.00% per year.

Back to Basics: PB Ratio


Samsung BioLogics Co PB Ratio Historical Data

The historical data trend for Samsung BioLogics Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co PB Ratio Chart

Samsung BioLogics Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.88 11.97 6.50 5.50 6.19

Samsung BioLogics Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.50 5.91 5.01 6.57 6.19

Competitive Comparison of Samsung BioLogics Co's PB Ratio

For the Biotechnology subindustry, Samsung BioLogics Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samsung BioLogics Co's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's PB Ratio falls into.


;
;

Samsung BioLogics Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Samsung BioLogics Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=1045000.00/153211.511
=6.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Samsung BioLogics Co  (XKRX:207940) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Samsung BioLogics Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Samsung BioLogics Co Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines